Manipulating Aggregation Behavior of the Uncharged Peptide Carbetocin

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Manipulating Aggregation Behavior of the Uncharged Peptide Carbetocin. / Høgstedt, Ulrich B; Østergaard, Jesper; Weiss, Torsten; Sjögren, Helen; van de Weert, Marco.

In: Journal of Pharmaceutical Sciences, Vol. 107, No. 3, 03.2018, p. 838-847.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Høgstedt, UB, Østergaard, J, Weiss, T, Sjögren, H & van de Weert, M 2018, 'Manipulating Aggregation Behavior of the Uncharged Peptide Carbetocin', Journal of Pharmaceutical Sciences, vol. 107, no. 3, pp. 838-847. https://doi.org/10.1016/j.xphs.2017.11.008

APA

Høgstedt, U. B., Østergaard, J., Weiss, T., Sjögren, H., & van de Weert, M. (2018). Manipulating Aggregation Behavior of the Uncharged Peptide Carbetocin. Journal of Pharmaceutical Sciences, 107(3), 838-847. https://doi.org/10.1016/j.xphs.2017.11.008

Vancouver

Høgstedt UB, Østergaard J, Weiss T, Sjögren H, van de Weert M. Manipulating Aggregation Behavior of the Uncharged Peptide Carbetocin. Journal of Pharmaceutical Sciences. 2018 Mar;107(3):838-847. https://doi.org/10.1016/j.xphs.2017.11.008

Author

Høgstedt, Ulrich B ; Østergaard, Jesper ; Weiss, Torsten ; Sjögren, Helen ; van de Weert, Marco. / Manipulating Aggregation Behavior of the Uncharged Peptide Carbetocin. In: Journal of Pharmaceutical Sciences. 2018 ; Vol. 107, No. 3. pp. 838-847.

Bibtex

@article{d317496ecd134447a249a0ed5506a5f2,
title = "Manipulating Aggregation Behavior of the Uncharged Peptide Carbetocin",
abstract = "Peptides are usually administered through subcutaneous injection. For low potency drugs, this may require high concentration formulations increasing the risk of peptide aggregation, especially for compounds without any intrinsic chargeable groups. Carbetocin was used as a model to study the behavior of uncharged peptides at high concentrations. Manipulation of the aggregation behavior of 70 mg/mL carbetocin was attempted by selecting excipients which interact with hydrophobic groups in carbetocin, and cover hydrophobic surfaces and interfaces. Peptide aggregation was induced by shaking stress and followed over time. Carbetocin solutions showed significant visible particle formation already after 4 h of shaking stress. This particle formation was not due to supersaturation or phase separation but suggested a nucleated aggregation process. None of the excipients prevented carbetocin aggregation, though altered aggregation behavior was observed, such as induction of fibril formation for most, but not all, charged excipients. Sodium dodecyl sulfate was found to accelerate peptide aggregation both below and above the critical micelle concentration in half-filled vials. However, in the absence of an air headspace, sodium dodecyl sulfate above the critical micelle concentration was capable of preventing shaking-induced carbetocin aggregation. Our study highlights the complexity in rational excipient selection to stabilize uncharged peptides at high concentration.",
author = "H{\o}gstedt, {Ulrich B} and Jesper {\O}stergaard and Torsten Weiss and Helen Sj{\"o}gren and {van de Weert}, Marco",
note = "Copyright {\circledC} 2018 American Pharmacists Association{\circledR}. Published by Elsevier Inc. All rights reserved.",
year = "2018",
month = "3",
doi = "10.1016/j.xphs.2017.11.008",
language = "English",
volume = "107",
pages = "838--847",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Manipulating Aggregation Behavior of the Uncharged Peptide Carbetocin

AU - Høgstedt, Ulrich B

AU - Østergaard, Jesper

AU - Weiss, Torsten

AU - Sjögren, Helen

AU - van de Weert, Marco

N1 - Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

PY - 2018/3

Y1 - 2018/3

N2 - Peptides are usually administered through subcutaneous injection. For low potency drugs, this may require high concentration formulations increasing the risk of peptide aggregation, especially for compounds without any intrinsic chargeable groups. Carbetocin was used as a model to study the behavior of uncharged peptides at high concentrations. Manipulation of the aggregation behavior of 70 mg/mL carbetocin was attempted by selecting excipients which interact with hydrophobic groups in carbetocin, and cover hydrophobic surfaces and interfaces. Peptide aggregation was induced by shaking stress and followed over time. Carbetocin solutions showed significant visible particle formation already after 4 h of shaking stress. This particle formation was not due to supersaturation or phase separation but suggested a nucleated aggregation process. None of the excipients prevented carbetocin aggregation, though altered aggregation behavior was observed, such as induction of fibril formation for most, but not all, charged excipients. Sodium dodecyl sulfate was found to accelerate peptide aggregation both below and above the critical micelle concentration in half-filled vials. However, in the absence of an air headspace, sodium dodecyl sulfate above the critical micelle concentration was capable of preventing shaking-induced carbetocin aggregation. Our study highlights the complexity in rational excipient selection to stabilize uncharged peptides at high concentration.

AB - Peptides are usually administered through subcutaneous injection. For low potency drugs, this may require high concentration formulations increasing the risk of peptide aggregation, especially for compounds without any intrinsic chargeable groups. Carbetocin was used as a model to study the behavior of uncharged peptides at high concentrations. Manipulation of the aggregation behavior of 70 mg/mL carbetocin was attempted by selecting excipients which interact with hydrophobic groups in carbetocin, and cover hydrophobic surfaces and interfaces. Peptide aggregation was induced by shaking stress and followed over time. Carbetocin solutions showed significant visible particle formation already after 4 h of shaking stress. This particle formation was not due to supersaturation or phase separation but suggested a nucleated aggregation process. None of the excipients prevented carbetocin aggregation, though altered aggregation behavior was observed, such as induction of fibril formation for most, but not all, charged excipients. Sodium dodecyl sulfate was found to accelerate peptide aggregation both below and above the critical micelle concentration in half-filled vials. However, in the absence of an air headspace, sodium dodecyl sulfate above the critical micelle concentration was capable of preventing shaking-induced carbetocin aggregation. Our study highlights the complexity in rational excipient selection to stabilize uncharged peptides at high concentration.

U2 - 10.1016/j.xphs.2017.11.008

DO - 10.1016/j.xphs.2017.11.008

M3 - Journal article

C2 - 29162423

VL - 107

SP - 838

EP - 847

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 3

ER -

ID: 191688476